| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| ursolic acid | corticosteroid 11-beta-dehydrogenase 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Metabolic Syndrome X[MeSHID:D024821] |
1.18 | phase 2 | unknown |
| ursolic acid | phospholipase a2 | NA | Successful target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Metabolic Syndrome X[MeSHID:D024821] |
NA | phase 2 | unknown |
| ursolic acid | ptpn1 messenger rna | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Metabolic Syndrome X[MeSHID:D024821] |
0.44 | phase 2 | unknown |
| ursolic acid | glycogen phosphorylase muscle form | NA | Patented-recorded target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Metabolic Syndrome X[MeSHID:D024821] |
NA | phase 2 | unknown |
| click here to return to the previous page | ||||||||